Hua Medicine has issued a positive profit alert, indicating a significant financial turnaround. According to the preliminary assessment of the unaudited management accounts for the six months ending June 30, 2025, the company anticipates recording a profit of approximately RMB1,184.1 million. This marks a notable improvement from the loss of approximately RMB142.0 million for the same period in 2024. The profit gain is largely attributed to the termination of an exclusive promotion service agreement with Bayer, resulting in the release of unamortized contract liabilities amounting to RMB1,243.5 million. Additionally, the company has assumed full responsibility for the commercialization of HuaTangNing in mainland China, supported by the recruitment of an experienced pharmaceutical sales executive. Investors and shareholders are advised to refer to the company's interim results announcement in August 2025 for more details.